March 28th 2024
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Gives Priority Review to Enzalutamide in Non-Metastatic HSPC
August 23rd 2023The FDA sets a Prescription Drug User Fee Act date in the fourth quarter of 2023 for its decision regarding enzalutamide as a treatment for those with non-metastatic hormone-sensitive prostate cancer with a high-risk of biochemical recurrence.
FDA Approves FoundationOne CDx for Niraparib/Abiraterone in BRCA+ mCRPC
August 17th 2023The FDA companion diagnostic designation for FoundationOne CDx may improve access to treatment with niraparib/abiraterone acetate dual action tablets in those with metastatic castration-resistant prostate cancer harboring a BRCA mutation.
PSMA PET Agent Flotufolastat F 18 Added to NCCN Prostate Cancer Guidelines
July 26th 2023Flotufolastat F 18 is indicated for use in imaging PSMA-positive prostate cancer lesions in patients who are likely to have metastatic disease and may be able to undergo initial definitive therapy, as well as those who may have recurrent disease.
DEAR Study Offers ‘Hope’ to Patients With Non-Metastatic CRPC
June 23rd 2023Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Talazoparib/Enzalutamide Improves Survival Vs Placebo in HRR mCRPC
June 4th 2023Talazoparib plus enzalutamide appears to improve the objective response rate vs enzalutamide plus placebo among patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair mutations in the phase 3 TALAPRO-2 study.
Metachronous Low Disease Volume May Result in Better Prostate Cancer Prognosis
May 28th 2023Synchronous disease appears to have a more hormone dependent transcriptional profile than metachronous disease, according to a retrospective review of patients with metastatic castration-sensitive prostate cancer.
PSA Decline With Apalutamide Yields Improved Survival in Prostate Cancer
May 10th 2023A post hoc analysis of the phase 3 TITAN trial highlights an association between PSA decline and survival among patients with metastatic castration-sensitive prostate cancer who were treated with apalutamide plus androgen deprivation therapy.
STAD Fails to Improve Survival Over Radiotherapy Alone in Prostate Cancer
April 30th 2023The addition of short-term androgen deprivation to dose-escalated radiation therapy did not yield a significant difference in quality-of-life outcomes vs radiotherapy alone for those with intermediate-risk prostate cancer, according to an expert from Henry Ford Health Cancer.